Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

Abstract:

:The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approved immunotherapy for prostate cancer of any indication to date. Given the continued need to improve therapeutics in patients with advanced prostate cancer, as well as recent enthusiasm for cancer immunotherapy, there is a wide range of ongoing trials evaluating combinations of sipuleucel-T with other therapeutics. Additional trials are aiming to expand the application of sipuleucel-T to prostate cancer patients beyond the mCRPC setting. Ongoing challenges include understanding the full mechanism of action of sipuleucel-T, optimizing the sequence of sipuleucel-T in relation to other therapies for mCRPC in clinical practice, and the identification of surrogate markers to predict survival benefit in clinical trials.

journal_name

Expert Rev Vaccines

authors

Wei XX,Fong L,Small EJ

doi

10.1586/14760584.2015.1099437

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1529-41

issue

12

eissn

1476-0584

issn

1744-8395

journal_volume

14

pub_type

杂志文章,评审
  • Developmental immunology and vaccines: cellular immune development and future vaccine strategies.

    abstract::This section deals with how new knowledge of the development of cellular immunity in the neonatal period informs vaccine development and reviews the immune responses of the most vulnerable group of newborns, those born prematurely, to vaccines. It describes how the development of future vaccine strategies relies on a ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.339

    authors: Prescott S

    更新日期:2004-08-01 00:00:00

  • In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

    abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1599286

    authors: Berkhout A,Clark JE,Wen SC

    更新日期:2019-05-01 00:00:00

  • Current vaccine updates for lung cancer.

    abstract::Current treatments for lung cancer are far from optimal. Several immunotherapeutic strategies involving vaccines incorporating different tumor-associated antigens to induce immune responses against tumors are being tested in clinical trials internationally. Although small, benefits have indeed been observed from the e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.12

    authors: Simmons O,Magee M,Nemunaitis J

    更新日期:2010-03-01 00:00:00

  • Bioreactor concepts for cell culture-based viral vaccine production.

    abstract::Vaccine manufacturing processes are designed to meet present and upcoming challenges associated with a growing vaccine market and to include multi-use facilities offering a broad portfolio and faster reaction times in case of pandemics and emerging diseases. The final products, from whole viruses to recombinant viral ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1067144

    authors: Gallo-Ramírez LE,Nikolay A,Genzel Y,Reichl U

    更新日期:2015-01-01 00:00:00

  • Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

    abstract::Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhanceme...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.142

    authors: Borrow R,Dagan R,Zepp F,Hallander H,Poolman J

    更新日期:2011-11-01 00:00:00

  • Pediatric combined formulation DTaP-IPV/Hib vaccine.

    abstract::Combination vaccines have been used for many years in the USA as part of the primary infant immunization series. However, the current program still requires up to 24 injections by 18 months of age. The Advisory Committee on Immunization Practices in the USA recommends the use of combination vaccines whenever possible....

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.59

    authors: White C,Halperin SA,Scheifele DW

    更新日期:2009-07-01 00:00:00

  • Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.

    abstract::Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, differen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.862499

    authors: Talebian Yazdi M,Keene KR,Hiemstra PS,van der Burg SH

    更新日期:2014-01-01 00:00:00

  • Challenges of Global Vaccine Development.

    abstract::The Keystone Symposia conference, Challenges of Global Vaccine Development, attracted approximately 440 scientists, physicians and students from all around the world. The conference goal was to share newly acquired knowledge regarding vaccine-induced immunity, novel technologies, childhood vaccines, preclinical models...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/14760584.7.1.21

    authors: Gudmundsdotter L,Hallengärd D

    更新日期:2008-02-01 00:00:00

  • Chinese vaccine products go global: vaccine development and quality control.

    abstract::Through the continuous efforts of several generations, China has become one of the few countries in the world that is capable of independently addressing all the requirements by the Expanded Program on Immunization. Regulatory science is applied to continuously improve the vaccine regulatory system. Passing the prequa...

    journal_title:Expert review of vaccines

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14760584.2015.1012503

    authors: Xu M,Liang Z,Xu Y,Wang J

    更新日期:2015-05-01 00:00:00

  • New challenges in therapeutic vaccines against HIV infection.

    abstract:INTRODUCTION:There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1322513

    authors: Leal L,Lucero C,Gatell JM,Gallart T,Plana M,García F

    更新日期:2017-06-01 00:00:00

  • Current challenges for cancer vaccine adjuvant development.

    abstract:INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1434000

    authors: Bowen WS,Svrivastava AK,Batra L,Barsoumian H,Shirwan H

    更新日期:2018-03-01 00:00:00

  • Mobilizing and evaluating anticancer T cells: pitfalls and solutions.

    abstract::Immunotherapy is a promising means to fight cancer, prompting a steady increase in clinical trials and correlative laboratory studies in this field. As antitumor T cells play central roles in immunity against malignant diseases, most immunotherapeutic protocols aim to induce and/or strengthen their function. Various t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2013.843456

    authors: Robert-Tissot C,Nguyen LT,Ohashi PS,Speiser DE

    更新日期:2013-11-01 00:00:00

  • Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae.

    abstract::Nontypeable Haemophilus influenzae (NTHi) is a predominant organism of the upper respiratory nasopharyngeal microbiota. Its disease spectrum includes otitis media, sinusitis, non-bacteremic pneumonia and invasive infections. Protein-based vaccines to prevent NTHi infections are needed to alleviate these infections in ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1156539

    authors: Khan MN,Ren D,Kaur R,Basha S,Zagursky R,Pichichero ME

    更新日期:2016-07-01 00:00:00

  • Usefulness of influenza vaccination during pregnancy to mothers and young infants.

    abstract::As pregnant women are at increased risk of influenza infection and influenza-related complications, immunization with inactivated influenza vaccine during the influenza season is recommended. Vaccination during pregnancy is considered to provide benefits for both the mothers and their young infants. In 2009, the novel...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.67

    authors: Hisano M,Yamaguchi K

    更新日期:2012-08-01 00:00:00

  • CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.

    abstract::Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by coadministered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA), the licensed human vaccine, can increase the speed, magnitude and avidity of the resultant anti-ant...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.3.365

    authors: Klinman DM

    更新日期:2006-06-01 00:00:00

  • The fundamental link between pneumococcal carriage and disease.

    abstract::Streptococcus pneumoniae (pneumococcus) is a major cause of worldwide mortality and morbidity, and to a large extent is vaccine-preventable. Nasopharyngeal carriage of pneumococcus precedes disease and is the source of pneumococcal spread between people. The use of vaccine effect on carriage as part of the vaccine lic...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.53

    authors: Simell B,Auranen K,Käyhty H,Goldblatt D,Dagan R,O'Brien KL,Pneumococcal Carriage Group.

    更新日期:2012-07-01 00:00:00

  • Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review.

    abstract:BACKGROUND:Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. OBJECTIVE:To describe the vaccine efficacy, immunoge...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1150182

    authors: Bakker M,Bunge EM,Marano C,de Ridder M,De Moerlooze L

    更新日期:2016-07-01 00:00:00

  • Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.

    abstract::Dr Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (BTG; Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/erv.10.2

    authors: Ben-Yedidia T

    更新日期:2010-03-01 00:00:00

  • Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.

    abstract::Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-leve...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.88

    authors: Bassett JD,Swift SL,Bramson JL

    更新日期:2011-09-01 00:00:00

  • Vaccination and immunization against travel-related diseases in immunocompromised hosts.

    abstract::Immunocompromised hosts are growing in number and include transplant recipients of solid organs or hematopoietic stem cells, people who have HIV, cancer patients on chemotherapy, patients on immunomodulatory treatments for rheumatologic, gastrointestinal or other conditions, as well as those with other immunocompromis...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.5.663

    authors: Kotton CN

    更新日期:2008-07-01 00:00:00

  • Trends in vaccine adjuvants.

    abstract::Adjuvants are essential components of most clinically used vaccines. This is because the majority of nonliving vaccines are relatively poor inducers of adaptive immunity unless effective adjuvants are co-administered. Aluminum salts (alum) have been used as adjuvants with great success for almost a century and have be...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.21

    authors: Schijns VE,Lavelle EC

    更新日期:2011-04-01 00:00:00

  • Insect cell technology is a versatile and robust vaccine manufacturing platform.

    abstract::Baculovirus and insect cell culture technologies have mostly been limited to research laboratories for the transient expression of target proteins for drug development purposes. With the renaissance of the vaccine field and the regulatory acceptance of recombinant DNA technology, the baculovirus expression system has ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.24

    authors: Mena JA,Kamen AA

    更新日期:2011-07-01 00:00:00

  • Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.

    abstract:INTRODUCTION:Pneumococcal conjugate vaccine (PCV) impact studies have reported substantial reductions in the incidence of invasive pneumococcal disease (IPD) after implementation of childhood PCV programs. Heterogeneity in surveillance systems, local epidemiology and PCV programs hampers comparisons between studies. We...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1413354

    authors: Izurieta P,Bahety P,Adegbola R,Clarke C,Hoet B

    更新日期:2018-06-01 00:00:00

  • Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

    abstract::Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.9.1367

    authors: Dinleyici EC,Yargic ZA

    更新日期:2008-11-01 00:00:00

  • Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

    abstract:INTRODUCTION:Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1507743

    authors: Sano K,Ainai A,Suzuki T,Hasegawa H

    更新日期:2018-08-01 00:00:00

  • The RTS,S vaccine candidate for malaria.

    abstract::Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine for...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.57

    authors: Regules JA,Cummings JF,Ockenhouse CF

    更新日期:2011-05-01 00:00:00

  • Challenges in estimating influenza vaccine effectiveness.

    abstract::Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1622419

    authors: Ainslie KEC,Haber M,Orenstein WA

    更新日期:2019-06-01 00:00:00

  • Streptococcus pneumoniae serotype 19A: worldwide epidemiology.

    abstract:INTRODUCTION:Streptococcus pneumoniae causes mucosal and invasive diseases with high morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) into routine infant immunization programs worldwide resulted in serotype 19A becoming a leading cause of the remaining pneumococcal disease bur...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1362339

    authors: Isturiz R,Sings HL,Hilton B,Arguedas A,Reinert RR,Jodar L

    更新日期:2017-10-01 00:00:00

  • Perspectives on vaccination in adults.

    abstract::In the Second Conference on Controversies in Vaccination in Adults, leading vaccine experts among manufacturers, physicians, microbiologists, virologists, immunologists and public health specialists came together to discuss recent approaches, developments and strategies in vaccination against worldwide pressing epidem...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.13.44

    authors: Doerr HW

    更新日期:2013-06-01 00:00:00

  • Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.

    abstract::There is growing interest in immunotherapy for malignant gliomas. This interest stems from a number of immunological observations, together with the failure of conventional therapeutic agents to produce broad and clinically meaningful improvements in survival and quality of life. The challenges faced in translating la...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.881255

    authors: Fenstermaker RA,Ciesielski MJ

    更新日期:2014-03-01 00:00:00